Abstract: Composition for topical use including a gelled phase dispersed in a continuous phase, with: the gelled phase including a diol having 3-8 atoms and represented either by formula (Ia): Ra1-C(Rb1)(OH)—C(OH)(Rc1)(Rd1) (Ia), in which each of the Ra1, Rb1, Rc1 and Rd1 radicals represent, independently of one another, a hydrogen atom or saturated aliphatic radical having 1-5 carbon atoms, or by formula (Ib): Ra1-C(Rb1)(OH)—[C(Re1)(Rf1)]t-C(OH)(Rc1)(Rd1) (Ib), in which t is equal to one, two or three, each of the Ra1, Rb1, Rc1, Rd1, Re1 and Rf1 radicals represent, independently of one another, a hydrogen atom or saturated aliphatic radical having 1-5 carbon atoms, it being understood that at least one of the Ra1 or Rb1 radicals and/or at least one of the Rc1 or Rd1 radicals do not represent a hydrogen atom, and —a fatty phase including an oil, an emulsifying surfactant system and an emulsifying surfactant.

Abstract: Topical pharmaceutical composition as a dispersed phase based on a short diol in a continuous fatty phase and including an anti-inflammatory substance, the composition including: a gelled phase including an anti-inflammatory substance and a diol including 3-8 carbon atoms and represented either by formula (Ia): Ra1—(Rb1)(OH)—(OH)(Rc1)(Rd1) (Ia), in which each of the radicals Ra1, Rb1, Rc1 and Rd1 represents, independently of each other, a hydrogen atom or a saturated aliphatic radical including 1-5 carbon atoms, or by formula (Ib): Ra1—C(Rb1)(OH)—[C(Re1)(Rf1)]t—C(OH)(Rc1)(Rd1) (Ib), t=1, 2 or 3, each of the radicals Ra1, Rb1, Rc1 Rd1, Re1 and Rf1 represents, independently of each other, a hydrogen atom or a saturated aliphatic radical including 1-5 carbon atoms. The radicals Ra1or Rb1 and/or the radicals Rc1or Rd1does not represent a hydrogen atom, a fatty phase including an oil and an emulsifying system including a combination of emulsifying surfactants.

Abstract: Disclosed is a pharmaceutical composition for topical. use in the form of a water-in-oil emulsion including, for 100% of the weight thereof: from 0.3% to 5% by weight of at least one azolated local antifungal substance;—from 60% to 90% by weight of a gelled aqueous phase (A1);—from 9.7% to 35% by weight of a fatty phase (A2) including at least one oil and an emulsifying system including a combination of at least one emulsifying surfactant (S1) selected from the elements of the group consisting of alkylpolyglycoside compositions and alkylpolyglycoside and fatty alcohol compositions, and of at least one emulsifying surfactant (S2) selected from the elements of the group consisting of polyglycerol esters, alkoxylated polyglycerol esters, polyglycol polyhydroxystearates, polyglycerol polyhydroxystearates and alkoxylated polyglycerol polyhydroxystearates.

Abstract: A pharmaceutical composition for topical use which is in the form of a water-in-oil emulsion including, for 100% of the weight thereof: —from 0.3% to 5% by weight of at least one local anaesthetic substance; —from 60% to 90% by weight of gelled aqueous phase; —from 9.7% to 35% by weight of a fatty phase including at least one oil and an emulsifying system including a combination of at least one emulsifying surfactant selected from the elements of the group consisting of alkylpolyglycoside compositions and alkylpolyglycoside and fatty alcohol compositions, and of at least one emulsifying surfactant selected from the elements of the group consisting of polyglycerol esters, alkoxylated polyglycerol esters, polyglycol polyhydroxystearates, polyglycerol polyhydroxystearates and alkoxylated polyglycerol polyhydroxystearates.

Abstract: A pharmaceutical composition for topical use which is in the form of a water-in-oil emulsion including, for 100% of the weight thereof: —from 60% to 80% by weight of a gelled aqueous phase including an anti-inflammatory substance, —from 20% to 40% by weight of a fatty phase including at least one oil and an emulsifying system including a combination of at least one emulsifying surfactant selected from the elements of the group consisting of alkylpolyglycoside compositions and alkylpolyglycoside and fatty alcohol compositions, and of at least one emulsifying surfactant selected from the elements of the group consisting of polyglycerol esters, alkoxylated polyglycerol esters, polyglycol polyhydroxystearates, polyglycerol polyhydroxystearates and alkoxylated polyglycerol polyhydroxystearates.

Abstract: Disclosed is a disinfecting composition for topical use, including a surfactant mixture based on cocoyl glutamate and alkyl polyglycosides, at least one thickening and/or gelling agent, and at least one disinfectant.

Abstract: A texturizing composition and method utilized for foundations, makeup powders, mascaras, lipsticks, emulsions, lotions, gels, sprayable formulations, and solutions impregnated on fabrics, paper, towelettes or complexion corrector papers comprising at least one self-invertible inverse latex, and powder.

Abstract: A texturizing composition and method utilized for foundations, makeup powders, mascaras, lipsticks, emulsions, lotions, gels, sprayable formulations, and solution impregnated on fabrics, paper, towelettes or complexion corrector papers comprising at least one self-invertible inverse latex, and powder.

Abstract: Use of a polymer or of a blend of polymers chosen from copolymers or terpolymers of methyl methacrylate with one or more monomers chosen from acrylic acid esters or methacrylic acid esters, as a texturing agent in cosmetic or pharmaceutical compositions formulated in the form of powders that may be applied to the human or animal body. Cosmetic or pharmaceutical composition containing it, and use thereof as makeup products.

Abstract: A texturizing composition and method utilized for foundations, makeup powders, mascaras, lipsticks, emulsions, lotions, gels, sprayable formulations, and solutions impregnated on fabrics, paper, towelettes or complexion corrector papers comprising at least one self-invertible inverse latex, and powder.

Abstract: Use of a polymer or of a blend of polymers chosen from copolymers or terpolymers of methyl methacrylate with one or more monomers chosen from acrylic acid esters or methacrylic acid esters, as a texturing agent in cosmetic or pharmaceutical compositions formulated in the form of powders that may be applied to the human or animal body. Cosmetic or pharmaceutical composition containing it, and use thereof as makeup products.

Abstract: The present invention relates to compositions based on alkyl polyglycosides and fatty alcohols, characterized in that they comprise: *5 to 60% by weight of a mixture of alkyl polyglycosides constituted essentially of: −30 to 95% by weight of a mixture of alkyl polyglycosides of formulae (I) and (II): R1O(G1)x1  (I) R2O(G2)x2  (II) in which R1 and R2 each represent a linear or branched aliphatic radical having 16 and 18 carbon atoms respectively, G1 and G2 each represent a saccharide residue, and x1 and x2 each represent a number between 1 and 5; −70 to 5% by weight of a mixture of alkyl polyglycosides of formulae (III) and (IV): R3O(G3)x3  (III) R4O(G4)x4  (IV) in which R3 and R4 each represent a linear or branched aliphatic radical having 20 and 22 carbon atoms respectively, G3 and G4 each represent a saccharide residue, x3 and x4 each represent a number between 1 and 5; *95 to 40% by weight of one or more alcohols of formula R′OH, in which R&pr